Articles On Cann Group (ASX:CAN)
Title | Source | Codes | Date |
---|---|---|---|
Cann Group CEO resigns after just 14 months at the helm
Cann Group (ASX: CAN) CEO Peter Koetsier has tendered his resignation just 14 months after assuming leadership of the medicinal cannabis company, which is growing sales at a fast clip but remains burdened by the debts incurred as a result o... |
businessnewsaustralia.com | CAN | 1 week ago |
Playing with fire: The dangers of chasing hot trends
Content Director Patrick Poke of Betashares explores the risks associated with impulsively reacting to investment trends fuelled by media hype, and explain why prudent asset selection, diversification, and maintaining a composed approach ar... |
Rask Media | CAN | 1 week ago |
Weed Week: Cannabis can ‘kill melanoma’; and Germany legalises weed possession
Study shows cannabis can kill melanoma cells Germany has voted to legalise cannabis possession The best performing ASX weed stocks over the past month It hasn’t been a stellar month for global cannabis stocks, with the index falling by... |
Stockhead | CAN | 3 weeks ago |
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month
ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr... |
Stockhead | CAN | 3 weeks ago |
Going concerns notices raised for ASX cannabis players Cann Group and Althea
Material uncertainties have been raised about two of the largest medicinal cannabis companies listed on the ASX to continue as going concerns, after Cann Group (ASX: CAN) and Althea Group (ASX: AGH) incurred December half losses of $14.3 mi... |
businessnewsaustralia.com | CAN | 3 weeks ago |
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks There were a couple of big news from the world of biotec... |
Stockhead | CAN | 1 month ago |
Weed Week: Iron Mike throws down challenge to Biden, and recent ASX pot winners
Mike Tyson has spoken out against the jailing of cannabis users Iron Mike owns his own cannabis brand called TYSON 2.0 We take a look at the best performing ASX weed stocks over the past month There are currently at least 3,000 individ... |
Stockhead | CAN | 1 month ago |
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
Xi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks China’s President Xi is expected... |
Stockhead | CAN | 4 months ago |
Weed Week: Jamaican nettletree could be a new, cheaper option to source CBD, says scientists
Jamaican nettletree is said to contain traces of cannabidiol (CBD) Victoria set to launch a medical cannabis driving trial for patients How ASX weed stocks have performed over the past week and month Scientists in Brazil said they’ve d... |
Stockhead | CAN | 4 months ago |
Weed Week: US House Speaker ousting could boost weed stocks; TGA urged to allow the term ‘medicinal cannabis’
Cannabis stocks could rise after the removal of US House Speaker Montu says TGA has to allow the term ‘medicinal cannabis’ to be used We look at the best performing ASX weed stocks over the past month Some experts believe cannabis stock... |
Stockhead | CAN | 5 months ago |
Weed Week: Big win for cannabis as SAFER Banking Act approved; market remains robust in Australia
Big win for cannabis as SAFER Banking Act set to be passed in the US Australia’s cannabis industry remains robust this year, says TGA We look at how ASX weed stocks have performed over the past weeks A huge win for cannabis as US SAFER... |
Stockhead | CAN | 5 months ago |
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it
L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks Be... |
Stockhead | CAN | 6 months ago |
Weed Week: Short sellers burned as cannabis stocks stage a rebound. Where to next?
Cannabis stocks are rebounding, catching short sellers off guard Next signpost for weed investors is the Section 280E of the US IRS tax code We take a look at the best performing weed stocks in last couple of weeks Having been mauled fo... |
Stockhead | CAN | 6 months ago |
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?
The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks On... |
Stockhead | CAN | 6 months ago |
Weed Week: Growing excitement for cannabis stocks after marijuana rescheduling hopes in the US
Cannabis stocks jumped after marijuana rescheduling recommendation in the US Study in Australia shows cannabis is effective on a range of conditions We take a look at the best performing ASX stocks over the past week Cannabis stocks ope... |
Stockhead | CAN | 6 months ago |
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…
Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August August was all about earnings, and des... |
Stockhead | CAN | 6 months ago |
Check Up: Australian biotech sector continues to be a magnet for US investors
Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the best and worst performing ASX biotechs over the past month The Australian biotech sector co... |
Stockhead | CAN | 6 months ago |
Weed Week: ‘Welcome to the psychedelic 2020s!’ as market holds breath on key US approval
The US is about to follow Australia’s footsteps and approve psychedelics The FDA is currently awaiting a pivotal survey conducted by MAPS And here’s how the ASX weed stocks have performed over the past week In July of this year, Austral... |
Stockhead | CAN | 7 months ago |
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go
Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month Steve Jobs used to say that the most... |
Stockhead | CAN | 7 months ago |
Weed Week: Mastercard says NO to cannabis transactions, as New York becomes the happening place for weed
Mastercard says no to weed transactions New York is where weed is happening Jeremy Buckingham pulls a stunt at NSW Parliament Here’s a quick snapshot of cannabis news making headlines over the past week: Mastercard has told banks to sto... |
Stockhead | CAN | 7 months ago |
ASX Health Stocks: Medibio jumps 50pc on Phase 1 results; Cann doubles cannabis harvest
Medibio jumps after completing Phase 1 clinical trial Cann Group’s latest crop harvest is at a scale twice that of previous harvests 4DMedical wins a $1.1 million from the Fed government Microcap Medibio (ASX:MEB) jumped 50% this mornin... |
Stockhead | CAN | 8 months ago |
Dragonfly Biosciences sprouts wings for ASX IPO
Dragonfly Biosciences Limited, a prominent UK-based producer of cannabidiol (CBD) supplements and lotions, is making strides towards its IPO on the ASX next month. Regan Saveall, the CEO of Dragonfly Biosciences, expressed enthusiasm about... |
ShareCafe | CAN | 8 months ago |
Weed Week: Social media platforms scramble to update advertising policies on cannabis products
Social media platforms are rushing to update their advertising policies on cannabis Meta was the most recent platform to do so Australia’s TGA is clamping down on CBD advertising in Australia With regulations on cannabis use moving fast... |
Stockhead | CAN | 8 months ago |
How Bod Science pulled ahead in the race for Australia’s first over-the-counter CBD
Since TGA’s down-scheduling of CBD last year, no products have been sold in Australia But the race to market has been seemingly won by Bod Science following a ‘landmark update’ Stockhead reached out to BOD’s CEO, Jo Patterson Amidst gro... |
Stockhead | CAN | 8 months ago |
Cann Group doubles sales as Mildura cannabis crop set to triple
Medicinal cannabis company Cann Group (ASX: CAN) will start harvesting again from its Mildura facility in mid-July, with yields set to lift substantially after a financial year when sales more than doubled to reach $13.5 million, bolstered... |
businessnewsaustralia.com | CAN | 8 months ago |
Cann Group lights up medicinal cannabis market
Cann Group (ASX:CAN), a prominent player in the Australian medicinal cannabis industry, has announced its unaudited revenue results for the fiscal year 2023, showcasing remarkable growth. The company expects unaudited operating revenue of a... |
ShareCafe | CAN | 8 months ago |
Cann Group lights up medicinal cannabis market
05 Jul 2023 - Cann Group (ASX:CAN) has announced its unaudited revenue results for the fiscal year 2023, showcasing remarkable growth. |
FNN | CAN | 8 months ago |
ASX Health Stocks: Cann’s cannabis flower sales grow 500pc; Immuron runs out of Travelan as travel rebounds
Cann Group’s FY23 sales were 2.1 times that of FY22 Immuron’s FY23 sales increased by 136% from the previous year Cann Group doubles its sales revenue Cannabis house Cann Group (ASX:CAN) rose 8% this morning after releasing its full yea... |
Stockhead | CAN | 8 months ago |
Why ASX cannabis shares just jumped back into the spotlight
ASX cannabis shares have had a tough year. Thatâs despite the fact that the cannabis stocks operate in a country where medicinal marijuana is technically legal. Thatâs enabled them to provide valuable health services to many thousands... |
Motley Fool | CAN | 9 months ago |
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines
Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month The world is anticipating a “game changer” as Brisba... |
Stockhead | CAN | 9 months ago |
Weed Week: Storm before the calm as cannabis market set to boom after SAFE Banking Act passed
The weed industry has slumped as it faces several headwinds But new data suggests the industry will grow significantly over the next decade We take a look at how the ASX weed stocks have performed over the past week As we head into the... |
Stockhead | CAN | 9 months ago |
CLOSING BELL: Remember to say thanks to the techies, without whom we’d be deep in the red for the day
Local markets shook off a post-long-weekend wobble to end the day higher, up 0.23% It’s been another red-hot day for the techies, with that sector up by 3.7%. Health techie AHI went flying 370% this morning, and it’s anyone’s guess as to w... |
Stockhead | CAN | 9 months ago |
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends
Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week When we talk about dividend-paying hea... |
Stockhead | CAN | 9 months ago |
Weed Week: A ‘shroom boom’ could see psychedelics follow cannabis’ explosive footsteps
The world is experiencing a ‘shroom boom’ Psychedelics are expected to follow in cannabis’ explosive footstep And here’s how the ASX weed stocks have performed, sorted by winners over the past week For years, people have frowned upon ps... |
Stockhead | CAN | 9 months ago |
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough
Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May There are clear signs the biotech sector is springing back to life after a disappointing 2... |
Stockhead | CAN | 9 months ago |
Check Up: Here’s how diabetes drugs can help you get off the beers and lose weight
Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week Earlier this week, Pfizer surprised the market by say... |
Stockhead | CAN | 10 months ago |
Weed Week: Cannabis helps chronic pain and insomnia, and here’s what the TGA rules say
Research in Australia shows marijuana helps with chronic pain and insomnia The rules around getting prescriptions for medicinal cannabis A quick look at the winners and losers of ASX weed stocks Sufferers of chronic pain and insomnia ha... |
Stockhead | CAN | 10 months ago |
Check Up Budget Edition: Which ASX healthcare stocks will reap benefits from the Budget?
The Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health and Telehealth also received significant funding allocations Here are the ASX stocks that could benefit Medicare, telehealth and mental... |
Stockhead | CAN | 10 months ago |
Weed Week: New studies confirm cannabis alleviates cancer pain, cuts need for opioids, and improves sleep
Studies confirm that cannabis relieves pain in cancer patients In addition, cannabis also improves sleep and cognitive function in cancer patients We take a look at the biggest movers in ASX weed stocks over the past week It’s now offic... |
Stockhead | CAN | 10 months ago |
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales
Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s... |
Stockhead | CAN | 10 months ago |
Weed Week: 420 reminds us that cannabis stocks may be down, but by no means out
The 420 Day is unofficially the World Marijuana Day, and we look at the possible origins of this day Cannabis stocks have been falling, but there’s still a lot of promise We take a look at the cannabis stocks on the ASX over the past week... |
Stockhead | CAN | 11 months ago |
Weed Week: Most Aussies still use illicit cannabis, but more are now turning to prescriptions
The number of Aussies using legal instead of illicit medical cannabis is rising The main reason for using prescribed medicinal cannabis was chronic pain, says Sydney Uni survey We take a look at what made the news in ASX weed stocks this p... |
Stockhead | CAN | 11 months ago |
WEED WEEK: Wellnex teams up with Chemist Warehouse for new cannabis products
Chemist Warehouse joins WNX JV to develop new cannabis products Neurotech launches new clinical program for its NTI164 drug in Rett Syndrome InhaleRx nabs approval for Phase 1 IRX211 clinical trial for Complex Regional Pain Syndrome Wel... |
Stockhead | CAN | 1 year ago |
Banking on pot: Minus one global investment house, Switzerland moves to legalise cannabis
The Swiss government has moved quickly to shore up its uniqueness as a centre of commerce – albeit one where the banks eat each other – and hurriedly green-lit (no pun) plans to legalise the sale and consumption of cannabis in Zurich, Switz... |
Stockhead | CAN | 1 year ago |
Buying ASX cannabis stocks? Here’s what the Victorian government is considering right now
ASX cannabis stocks provide a valuable service to the many thousands of Australians who benefit from the legal, medicinal benefits of their product. All told, the cannabis shares have grown, cured, and prepared medicinal marijuana products... |
Motley Fool | CAN | 1 year ago |
ASX Health Stocks: Most biotechs are still chasing maiden revenue, but here’s a few healthcare stocks with strong earnings
Alcidion increased sales significantly in the first half Cogstate sounds warning on outlook Probiotic had a super half Most biotech firms on the ASX are clinical stage companies, meaning they are still trying to prove that their drugs a... |
Stockhead | CAN | 1 year ago |
Weed Week: Musk gives the go-ahead for cannabis advertising on Twitter in the US
Twitter to allow cannabis companies to advertise in US states where it’s legal Elixnol comes out on top with CannaCare Health arbitration awarded in their favour Avecho expands CBD soft-gel capsule trials with the Lambert Initiative Twi... |
Stockhead | CAN | 1 year ago |
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care
The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry The US FDA announced last week that:... |
Stockhead | CAN | 1 year ago |
Weed Week: Codeine demand drops when recreational cannabis is legal, study finds
US States who allow recreational cannabis see less codeine demand WA GP wants Snoop Dogg to drop into parliament to chat cannabis reform Neurotech nabs pre-submission meeting with US FDA for CBD drug NTI164 A Cornell University study ha... |
Stockhead | CAN | 1 year ago |
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device
Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past... |
Stockhead | CAN | 1 year ago |